Israel Hodish, MD, PhD is an assistant professor in the Division of Metabolism, Endocrinology & Diabetes (MEND), University of Michigan Health System. Dr. Hodish received his bachelor and MD degrees at the Hadassah Medical School at the Hebrew University, Jerusalem, Israel, in 1996. Following residency training in internal medicine, Dr. Hodish completed his PhD degree in 2006 in the field of anti-angiogenic gene therapy at the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Dr. Hodish performed his fellowship training at the Division of Metabolism, Endocrinology and Diabetes, University of Michigan, and joined the faculty in 2007.
Dr. Hodish's area of greatest clinical expertise is in the management of endocrine diseases, particularly beta-cell related diseases, including diabetes and hypoglycemia.
Dr. Hodish is a co-founder of Hygieia Inc., located in Ann Arbor, Michigan. The company has created a novel system for accessible, safe, and effective insulin therapy. This system was designed to circumvent the main impediment in insulin management, namely lack of time and expertise in providing frequent insulin dosage adjustments.
